Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings LLC-A (NASDAQ: MDBH) operates a pioneering public venture platform bridging deep technology innovation with capital markets. This news hub provides investors and analysts with essential updates on the company's dual operational focus: its self-clearing broker-dealer platform with integrated intellectual property services, and its technology development arm nurturing early-stage ventures.
Discover real-time information on securities offerings, strategic partnerships, and technology commercialization efforts. The platform serves as a strategic resource for tracking MDBH's role in transforming pre-revenue deep tech concepts into public market opportunities through its unique combination of investment banking services and patent intelligence.
Key updates include developments in IP-driven due diligence, early-stage company financings, and market expansion initiatives. Content is curated to help stakeholders monitor the company's progress in building operational efficiencies while maintaining compliance with public market requirements.
Bookmark this page for ongoing insights into MDB Capital Holdings' community-driven investment model and its impact on emerging technology sectors. Regular updates ensure informed tracking of the company's position at the intersection of venture capital and public market innovation.
PatentVest has released a comprehensive report on the brain-computer interface (BCI) market, projected to exceed $400 billion in the US. The report analyzes over 2,160 patent families across 664 entities in the neurotechnology sector.
The market comprises $80 billion in high-acuity, early-adopting patient populations and $320 billion in potential long-term applications for neurological and psychiatric conditions. While Neuralink maintains high visibility, Synchron is establishing category leadership through minimally invasive platforms and targeted IP strategy across 10 jurisdictions.
The report highlights key players including INBRAIN, Blackrock, Precision Neuroscience, and Paradromics, who are securing market positions through differentiated technologies and IP consolidation. Academic institutions like Tianjin University, Stanford, and the University of California continue to hold foundational patents in neural signal processing and interface architecture.
MDB Capital Holdings (NASDAQ: MDBH) has released its Q4 and full-year 2024 update, highlighting significant operational achievements in the public venture platform space. Key accomplishments include:
- Successfully launched eXoZymes Inc (EXOZ) through IPO, maintaining ~47% ownership
- Expanded analyst team to 14 members, screening 8,964 companies and deeply examining 217 potential market leaders
- Grew shareholder base by 12% with 456 new brokerage accounts
- Increased assets under management from $2M to $44M
- Launched first self-clearing broker-dealer platform for public venture investing
- Expanded PatentVest client base from 3 to 8 clients
The company filed its Form 10-K on March 31, including consolidated financial results through November 14, 2024, when eXoZymes was deconsolidated following its IPO.
MDB Capital Holdings (NASDAQ: MDBH), a public venture platform specializing in deep technology companies, has scheduled a Zoom webinar to discuss its Q4 and full year 2024 financial results on Monday, March 31, 2025, at 4:30 p.m. Eastern Time.
The earnings conference call will be led by CEO and Co-Founder Christopher Marlett, along with other management team members. They will review recent developments, ongoing initiatives, and anticipated milestones, followed by a Q&A session. The company will release detailed financial results before the call.
Investors can access the webinar through pre-registration or via MDB's investor relations website at https://investors.mdb.com/.
PatentVest has released a new Pulse Report analyzing the AI data center patent landscape, revealing China's dominance with 77% of global patent filings. The report highlights that five of the top patent holders are Chinese companies.
The data center as a service market, valued at $71.92 billion in 2022, is projected to reach $431.43 billion by 2030. This growth is driven by increasing demand for AI-optimized infrastructure and energy-efficient computing innovations.
Key market factors include:
- Technology innovations in AI-specific chip architectures and cooling systems
- Surge in patent filings for foundational technologies
- Significant patent litigation cases, including Intel's $2.18 billion ruling and Netlist's $118 million lawsuit against Samsung
Enterprise data generation is expected to reach 1.2 million exabytes by 2025, driving the need for advanced AI infrastructure solutions focusing on high-performance computing and real-time data processing.
eXoZymes (Nasdaq: EXOZ), a company specializing in AI-engineered enzymes for transforming sustainable feedstock into chemicals, medicines, and biofuels, announced that CEO Michael Heltzen and team members will ring the Nasdaq closing bell on February 19, 2025. This ceremony commemorates their successful IPO, which closed on November 14, 2024, with shares priced at $8 per share.
The bell ringing ceremony will be broadcast live at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. The company views this milestone as a marker of transition into what they call the 'exozymes era of biotechnology,' following the synthetic biology era.
Invizyne Technologies announced its corporate rebranding to eXoZymes Inc, with its stock trading symbol changing from IZTC to EXOZ on the Nasdaq Capital Market. The company introduces 'exozymes' as a new scientific concept, positioning it as the successor to synthetic biology (SynBio), particularly focusing on industrial-scale production.
eXoZymes specializes in AI-engineered enzymes designed to operate outside living cells in bioreactors, transforming feedstocks into valuable chemicals, medicines, and biofuels. The company emphasizes this technology's potential to replace traditional chemical production methods with sustainable alternatives. The development process, powered by AI and enzymes, significantly reduces production timelines, with the company expecting to announce a new chemical development completed in just weeks.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced its corporate name change to eXoZymes, Inc. The company, currently trading under NASDAQ ticker IZTC, will change its ticker symbol to EXOZ, expected to take effect on February 12, 2025, pending final approvals.
The company will update its branding, including the corporate website, to reflect the new name. Existing shareholders are not required to take any action regarding the name and ticker symbol change. The CUSIP number for the company's common stock will remain unchanged.
PatentVest has released a comprehensive report on the Continuous Glucose Monitoring (CGM) market, highlighting significant growth prospects and technological innovations in diabetes care. The report reveals that the global CGM market, valued at $11.63 billion in 2024, is projected to reach $21 billion by 2029.
The analysis addresses the critical need for continuous glucose monitoring solutions, noting that diabetes affects 537 million adults worldwide, with projections reaching 783 million by 2045. Key market drivers include technological advancements in non-invasive monitoring, integration with mobile applications, and the emergence of over-the-counter (OTC) CGM products.
The report emphasizes the competitive landscape dominated by major players like Dexcom, Abbott, Medtronic, and Roche, highlighting their role in transforming diabetes management through innovation and strategic market positioning. A surge in patent filings and ongoing litigation trends underscore the market's competitive nature.
MDB Capital Holdings (NASDAQ: MDBH) provided its Q3 2024 operational update, highlighting significant achievements including the successful IPO of Invizyne Technologies where MDB retains 48% ownership. The company launched a collaboration with Mayo Clinic for an anti-senescence platform with 67% founding ownership. MDB enhanced its analysis capabilities, screening 8,751 companies and examining 217 potential market leaders. The company expanded its investor base by 15%, increased brokerage accounts by 450+, and grew assets under management from $2M to $28M. PatentVest client engagements increased from three to eight since 2023.
Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.
